The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment
Open accessAbstract
BACKGROUND: The metabolic effects of initial therapy for HIV-1 infection are important determinants of regimen selection. METHODS: Open-label study in 753 subjects randomized equally to efavirenz or lopinavir/ritonavir(r) plus two nucleoside reverse-transcriptase inhibitor (NRTI) vs. the NRTI-sparing regimen of lopinavir/r plus efavirenz. Zidovudine, stavudine, or tenofovir with lamivudine was selected prior to randomization. Metabolic outcomes through 96 weeks were lipoatrophy, defined as at least 20% loss in extremity fat, and fasting serum lipids. RESULTS: Lipoatrophy by dual-energy X-ray absorptiometry at week 96 occurred in 32% [95% confidence interval (CI) 25-39%] of subjects in the efavirenz plus two NRTIs arm, 17% (95% CI 12-24) in the lopinavir/r plus two NRTIs arm, and 9% (95% CI 5-14) in the NRTI-sparing arm (P < or = 0.023 for all comparisons). Varying the definition of lipoatrophy (> or =10 to > or =40% fat loss) and correction for baseline risk factors did not affect the significant difference in lipoatrophy between the NRTI-containing regimens. Lipoatrophy was most frequent with stavudine-containing regimens and least frequent with tenofovir-containing regimens (P < 0.001), which were not significantly different from the NRTI-sparing regimen. Total cholesterol increases at week 96 were greatest in the NRTI-sparing arm (median +57 mg/dl) compared with the other two arms (+32-33 mg/dl; P < 0.001). Use of lipid-lowering agents was more common (25 vs. 11-13%) in the NRTI-sparing arm. CONCLUSION: Lipoatrophy was more frequent with efavirenz than lopinavir/r when combined with stavudine or zidovudine, and less frequent when either drug was combined with tenofovir. Lipoatrophy was least frequent with the NRTI-sparing regimen, but this benefit was offset by greater cholesterol elevations and the need for lipid-lowering agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Carr, A., Samaras, K., Burton, S., Law, M., Freund, J., Chisholm, D. J., & Cooper, D. A. (1998) · AIDS · doi:10.1097/00002030-199807000-00003 · Cited by 2,370
Combination Antiretroviral Therapy and the Risk of Myocardial Infarction
(2003) · New England Journal of Medicine · doi:10.1056/nejmoa030218 · Cited by 1,678
Class of Antiretroviral Drugs and the Risk of Myocardial Infarction
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa062744 · Cited by 1,521 · cited 2×
“3 was seen per 39 mg/dl increase in total cholesterol [29].”
BackgroundGallant, J. E. (2004) · JAMA · doi:10.1001/jama.292.2.191 · Cited by 1,341
Cardiovascular Risk and Body-Fat Abnormalities in HIV-Infected Adults
Grinspoon, S., & Carr, A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041811 · Cited by 1,070
Class-Sparing Regimens for Initial Treatment of HIV-1 Infection
Riddler, S. A., Haubrich, R., DiRienzo, A. G., Peeples, L., Powderly, W. G., Klingman, K. L., Garren, K. W., George, T., Rooney, J. F., Brizz, B., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074609 · Cited by 680
Self-citationMallal, S. A., John, M., Moore, C. B., James, I. R., & McKinnon, E. J. (2000) · AIDS · doi:10.1097/00002030-200007070-00002 · Cited by 510
Clinical assessment of HIV-associated lipodystrophy in an ambulatory population
Lichtenstein, K. A., Ward, D. J., Moorman, A. C., Delaney, K. M., Young, B., Palella, F. J., Rhodes, P. H., Wood, K. C., & Holmberg, S. D. (2001) · AIDS · doi:10.1097/00002030-200107270-00008 · Cited by 427
An objective case definition of lipodystrophy in HIV-infected adults: a case-control study
Carr, A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12656-6 · Cited by 422
Fontas, E., van Leth, F., Sabin, C. A., Friis‐Møller, N., Rickenbach, M., d’Arminio Monforte, A., Kirk, O., Dupon, M., Morfeldt, L., Mateu, S., et al. (2004) · The Journal of Infectious Diseases · doi:10.1086/381783 · Cited by 337
Fat Distribution in Men With HIV Infection
(2005) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000182230.47819.aa · Cited by 328
Mallon, P. W., Miller, J., Cooper, D. A., & Carr, A. (2003) · AIDS · doi:10.1097/00002030-200305020-00005 · Cited by 313
HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management
Carr, A. (2003) · AIDS · doi:10.1097/00002030-200304001-00017 · Cited by 275
Nolan, D., Hammond, E., Martin, A., Taylor, L., Herrmann, S., McKinnon, E., Metcalf, C., Latham, B., & Mallal, S. (2003) · AIDS · doi:10.1097/00002030-200306130-00007 · Cited by 265
Pozniak, A. L., Gallant, J. E., DeJesus, E., Arribas, J. R., Gazzard, B., Campo, R. E., Chen, S.-S., McColl, D., Enejosa, J., Toole, J. J., et al. (2006) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000245886.51262.67 · Cited by 231
HIV lipodystrophy: prevalence, severity and correlates of risk in Australia
Miller, J., Carr, A., Emery, S., Law, M., Mallal, S., Baker, D., Smith, D., Kaldor, J., & Cooper, D. (2003) · HIV Medicine · doi:10.1046/j.1468-1293.2003.00159.x · Cited by 215
Mayer, K. H., Dube, M. P., Sprecher, D., Henry, W. K., Aberg, J. A., Torriani, F. J., Hodis, H. N., Schouten, J., Levin, J., Myers, G., et al. (2000) · Clinical Infectious Diseases · doi:10.1086/317429 · Cited by 197
Dubé, M. P., Parker, R. A., Tebas, P., Grinspoon, S. K., Zackin, R. A., Robbins, G. K., Roubenoff, R., Shafer, R. W., Wininger, D. A., Meyer, W. A., et al. (2005) · AIDS · doi:10.1097/01.aids.0000183629.20041.bb · Cited by 189
Mallon, P. W. G., Unemori, P., Sedwell, R., Morey, A., Rafferty, M., Williams, K., Chisholm, D., Samaras, K., Emery, S., Kelleher, A., et al. (2005) · The Journal of Infectious Diseases · doi:10.1086/429697 · Cited by 171
Wohl, D. A., McComsey, G., Tebas, P., Brown, T. T., Glesby, M. J., Reeds, D., Shikuma, C., Mulligan, K., Dube, M., Wininger, D., et al. (2006) · Clinical Infectious Diseases · doi:10.1086/507333 · Cited by 162
Podzamczer, D., Ferrer, E., Sanchez, P., Gatell, J. M., Casal, M. C., Fisac, C., Loncà, M., Sanz, J., Niubó, J., Veloso, S., et al. (2006) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31802bf122 · Cited by 136
Redefining Lipodystrophy Syndrome
Lichtenstein, K. A. (2005) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000167478.28051.3a · Cited by 131
Pharmacokinetic Properties of Nucleoside/Nucleotide Reverse Transcriptase Inhibitors
Piliero, P. J. (2004) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000137001.40505.56 · Cited by 94
Dubé, M. P., Komarow, L., Mulligan, K. M., Grinspoon, S. K., Parker, R. A., Robbins, G. K., Roubenoff, R., & Tebas, P. (2007) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181142d26 · Cited by 66
Self-citationShikuma, C. M., Yang, Y., Glesby, M. J., Meyer, W. A., Tashima, K. T., Ribaudo, H. J., Webb, N., Bastow, B., Kuritzkes, D. R., & Gulick, R. M. (2007) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318031d5a0 · Cited by 55
Smith Don, E., Hudson, J., Allison, M., Freund, J., Griffiths Matthew, R., Sue, K., Matthew, L., Andrew, C., Cooper David, A., & for the PIILR DEXA Group and Investigators (2003) · HIV Clinical Trials · doi:10.1310/wrl8-dwh1-7vql-ak81 · Cited by 17
Cited by
Thompson, M. A., Aberg, J. A., Hoy, J. F., Telenti, A., Benson, C., Cahn, P., Eron, J. J., Günthard, H. F., Hammer, S. M., Reiss, P., et al. (2012) · JAMA · doi:10.1001/jama.2012.7961 · Cited by 2,469
Antiretroviral therapy and management of HIV infection
Volberding, P. A., & Deeks, S. G. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60676-9 · Cited by 449
Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine
Cihlar, T., & Ray, A. S. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2009.09.014 · Cited by 375
Usach, I., Melis, V., & Peris, J. (2013) · Journal of the International AIDS Society · doi:10.7448/ias.16.1.18567 · Cited by 373
Lucas, G. M., Ross, M. J., Stock, P. G., Shlipak, M. G., Wyatt, C. M., Gupta, S. K., Atta, M. G., Wools-Kaloustian, K. K., Pham, P. A., Bruggeman, L. A., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu617 · Cited by 310
Metadata
- Authors
- Haubrich, R. H., Riddler, S. A., DiRienzo, A. G., Komarow, L., Powderly, W. G., Klingman, K., Garren, K. W., Butcher, D. L., Rooney, J. F., Haas, D. W., Mellors, J. W., & Havlir, D. V.
- Venue
- AIDS
- Published
- 2009-06-01
- Volume
- 23
- Issue
- 9
- Pages
- 1109-1118
- ISSN
- 0269-9370 (ISSN-L)
- OpenAlex
- W1984717040
- Cited by
- 254
- References
- 27
- FWCI
- 37.40
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.